CUE BIOPHARMA INC. - COMMON STOCK

Cue Biopharma to Host Business Update Call and Webcast

07 Nov 2022 08:00:02 By Nasdaq GlobeNewswire

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

05 Oct 2022 08:00:01 By Nasdaq GlobeNewswire

Cue Biopharma Granted FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

04 Oct 2022 08:00:01 By Nasdaq GlobeNewswire

Cue Biopharma to Present at Two September 2022 Scientific Conferences

07 Sep 2022 08:00:01 By Nasdaq GlobeNewswire

Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) - expressing cancers

22 Aug 2022 08:00:01 By Nasdaq GlobeNewswire

Cue Biopharma Reports Second Quarter 2022 Financial Results

04 Aug 2022 16:30:00 By Nasdaq GlobeNewswire

Cue Biopharma to Present at the Guggenheim I&I Spotlight Series

11 Jul 2022 08:00:00 By Nasdaq GlobeNewswire

Cue Biopharma to Present at the JMP Securities Life Sciences Conference

13 Jun 2022 08:00:01 By Nasdaq GlobeNewswire

Cue Biopharma to Present at the Jefferies Healthcare Conference

01 Jun 2022 08:00:00 By Nasdaq GlobeNewswire

Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

26 May 2022 17:00:00 By Nasdaq GlobeNewswire

Cue Biopharma Receives FDA Acceptance of Investigational New Drug (IND) Application for CUE-102 in Wilms’ Tumor 1 (WT1) - expressing cancers

11 May 2022 08:01:12 By Nasdaq GlobeNewswire

Cue Biopharma Reports First Quarter 2022 Financial Results

10 May 2022 16:30:00 By Nasdaq GlobeNewswire

Cue Biopharma to Present at the Upcoming Oppenheimer 32nd Annual Healthcare Conference

10 Mar 2022 08:00:02 By Nasdaq GlobeNewswire

Cue Biopharma to Present an Updated Overview of Immuno-STAT Platform at the 2022 Festival of Biologics World Immunotherapy Congress

02 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the Biophysical Society 2022 Annual Meeting

15 Feb 2022 08:00:01 By Nasdaq GlobeNewswire

Cue Biopharma Reports Two Objective Responses (1 cPR and 1uPR) in First Interim Update from Dose Escalation Portion of Ongoing Phase 1 Combination Study of CUE-101 and KEYTRUDA® in First Line Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer

26 Jan 2022 16:01:00 By Nasdaq GlobeNewswire

Cue Biopharma to Host Business Update Call and Webcast for Ongoing CUE-101 Clinical Trials

20 Jan 2022 08:00:01 By Nasdaq GlobeNewswire

Cue Biopharma and LG Chem Life Sciences Announce Development Milestone in Immuno-STAT Biologics Collaboration for CUE-102

05 Jan 2022 08:00:02 By Nasdaq GlobeNewswire

Cue Biopharma Announces Appointment of Patricia Nasshorn as Chief Business Officer

15 Dec 2021 08:00:01 By Nasdaq GlobeNewswire

Cue Biopharma to Present at JMP Securities Hematology and Oncology Summit

06 Dec 2021 08:00:03 By Nasdaq GlobeNewswire